{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:34:12Z","timestamp":1788878052940,"version":"build-2803163510"},"reference-count":19,"publisher":"Termedia Sp. z.o.o.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tuberculous meningitis (TBM) is a severe extra-pulmonary tuberculosis with high fatality. This meta-analysis aimed to assess the impact of linezolid on TBM treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched multiple databases for studies published up to May 18, 2024 comparing the effects of linezolid on TBM. Meta-analysis was conducted using Review Manager 5.4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our findings indicated that linezolid may reduce treatment failure risk (RR = 0.42 (0.20, 0.89), p = 0.02) and improve temperature recovery (RR = 1.56 (1.21, 2.02), p &lt; 0.001) in TBM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The analysis suggests a positive association between linezolid treatment and therapeutic improvements, with no significant adverse reactions reported.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/189905","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:31:46Z","timestamp":1720445506000},"page":"1038-1042","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis"],"prefix":"10.5114","volume":"20","author":[{"given":"Xiaoshu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China"},{"name":"Department of Respiratory and Critical Care Medicine, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China"},{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"ref-1210579","doi-asserted-by":"crossref","unstructured":"Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res 2019; 4: 167.","DOI":"10.12688\/wellcomeopenres.15535.1"},{"key":"ref-1210580","doi-asserted-by":"crossref","unstructured":"Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 2013; 12 :999-1010.","DOI":"10.1016\/S1474-4422(13)70168-6"},{"key":"ref-1210581","unstructured":"World Health Organization & World Health Organization. (2010). Treatment of tuberculosis: guidelines, 4th edition. World Health Organization. https:\/\/iris.who.int\/handle\/10665\/44165."},{"key":"ref-1210582","doi-asserted-by":"crossref","unstructured":"Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet 2019; 58: 1103-29.","DOI":"10.1007\/s40262-019-00764-2"},{"key":"ref-1210583","doi-asserted-by":"crossref","unstructured":"Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 2010; 90: 279-92.","DOI":"10.1016\/j.tube.2010.07.002"},{"key":"ref-1210584","doi-asserted-by":"crossref","unstructured":"Sahib A, Bhatia R, Srivastava MVP, et al. Escalate: Linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial. Tuberculosis 2023; 142: 102351.","DOI":"10.1016\/j.tube.2023.102351"},{"key":"ref-1210585","doi-asserted-by":"crossref","unstructured":"Sun F, Ruan Q, Wang J, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother 2014; 58: 6297-301.","DOI":"10.1128\/AAC.02784-14"},{"key":"ref-1210586","doi-asserted-by":"crossref","unstructured":"Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J 2016; 35: 607-10.","DOI":"10.1097\/INF.0000000000001114"},{"key":"ref-1210587","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 6: e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref-1210588","doi-asserted-by":"crossref","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"ref-1210589","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"ref-1210590","doi-asserted-by":"crossref","unstructured":"Fang MT, Su YF, An HR, et al. Decreased mortality seen in rifampicin\/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China. BMC Infect Dis 2021; 21: 1015.","DOI":"10.1186\/s12879-021-06705-4"},{"key":"ref-1210591","unstructured":"Aktas G. Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains. Arch Med Sci 2023; 19: 189-93."},{"key":"ref-1210592","doi-asserted-by":"crossref","unstructured":"Bigelow KM, Deitchman AN, Li SY, et al. Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis. J Infect Dis 2021; 223: 1855-64.","DOI":"10.1093\/infdis\/jiaa016"},{"key":"ref-1210593","doi-asserted-by":"crossref","unstructured":"Davis AG, Wasserman S, Stek C, et al. A phase 2a trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial. Clin Infect Dis 2023; 76: 1412-22.","DOI":"10.1093\/cid\/ciac932"},{"key":"ref-1210594","doi-asserted-by":"crossref","unstructured":"Mazanhanga M, Joubert A, Castel S, et al. Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis. Heliyon 2023; 9: e21962.","DOI":"10.1016\/j.heliyon.2023.e21962"},{"key":"ref-1210595","doi-asserted-by":"crossref","unstructured":"Perdig\u00e3o J, Maltez F, Machado D, et al. Beyond extensively drug-resistant tuberculosis in Lisbon, Portugal: a case of linezolid resistance acquisition presenting as an iliopsoas abscess. Int J Antimicrob Agents 2016; 48: 569-70.","DOI":"10.1016\/j.ijantimicag.2016.07.026"},{"key":"ref-1210596","doi-asserted-by":"crossref","unstructured":"Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am J Respir Crit Care Med 2022; 205: 1214-27.","DOI":"10.1164\/rccm.202107-1779OC"},{"key":"ref-1210597","doi-asserted-by":"crossref","unstructured":"Graciaa DS, Kipiani M, Magee MJ, et al. Linezolid exposure is associated with cytopenias in patients treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2022; 66: e0040822.","DOI":"10.1128\/aac.00408-22"}],"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-189905-112122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-189905-112122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:41:14Z","timestamp":1720446074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Efficacy-of-linezolid-in-the-treatment-of-tuberculous-meningitis-a-meta-analysis,189905,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"alternative-id":["189905"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/189905","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]}}}